A Feasibility Study of Postoperative Adjuvant Therapy of Carboplatin and Weekly Paclitaxel for Completely Resected Non-small Cell Lung Cancer

IntroductionRecent clinical trials have shown significant survival benefits from postoperative adjuvant therapy for respectable nonsmall cell lung cancer (NSCLC). However, evaluation of adjuvant chemotherapy with carboplatin combination is still uncertain. The purpose of the study was to test the feasibility of adjuvant chemotherapy with carboplatin and separate weekly paclitaxel after complete resection of pStage IB, II, IIIA NSCLC in a multicenter study.MethodsThe study was conducted from 2001 to 2006 in the outpatient setting. A total of 61 patients were enrolled. Patients received adjuvant chemotherapy with 4 cycles of carboplatin (AUC 5) on day 1 and paclitaxel (70 mg/m2) on day 1, 8, and 15 every 4 weeks. Primary endpoints were toxicity and chemotherapy compliance. Secondary endpoints were disease-free survival and overall survival.ResultsMore than 65% of eligible patients had pStage IIIA. The median number of chemotherapy cycles was 4 (range 1–4). Grade 3 or 4 toxicities of neutropenia were 34% (grade 4: 2%). Other hematologic adverse effects were extremely less frequent. Regarding the nonhematologic adverse effect, hair loss was frequent; however, peripheral neuralgia was less frequent. Treatment-related death was not registered. During median follow-up of 21 months, 24 patients developed recurrent disease. Estimated disease-free survival and overall survival at 2 years was 51.2% and 84.6%, respectively.ConclusionsPostoperative carboplatin and weekly paclitaxel showed favorable feasibility and acceptable toxicity in comparison with the cisplatin-containing regimen. Consequently, it is desirable that this regimen would be validated in a phase III clinical trial for NSCLC after curative resection

Annual report by The Japanese Association for Thoracic Surgery

All data regarding cardiovascular surgery and thoracic surgery were obtained from NCD, whereas data regarding esophageal surgery were collected from survey questionnaire by The Japanese Association for Thoracic Surgery forms because NCD of esophageal surgery does not include non-surgical cases (i.e., patients with adjuvant chemotherapy or radiation alone). Based on the change in data aggregation, there are several differences between this 2015 annual report and previous annual reports: the number of institutions decreased in each category from 578 (2014) to 568 (2015) in cardiovascular, from 762 to 714 in general thoracic and from 626 to 571 in esophageal surgery. Because more than two departments in the same institute registered their data to NCD individually, we cannot calculate correct number of institutes in this survey. Then, the response rate is not indicated in the category of cardiovascular surgery (Table 1), and the number of institutions classified by the operation number is also not calculated in the category of cardiovascular surgery (Table 2)

Effect of Gold Nanoparticle Radiosensitization on Plasmid DNA Damage Induced by High-Dose-Rate Brachytherapy.

Gold nanoparticles (AuNPs) are candidate radiosensitizers for medium-energy photon treatment, such as γ-ray radiation in high-dose-rate (HDR) brachytherapy. However, high AuNP concentrations are required for sufficient dose enhancement for clinical applications. Here, we investigated the effect of positively (+) charged AuNP radiosensitization of plasmid DNA damage induced by 192Ir γ-rays, and compared it with that of negatively (-) charged AuNPs

An outline of separated calibration service currently under development

我が国の治療用線量計の2次校正機関である医用原子力財団では，校正サービスの次のステップとして，電位計と電離箱のそれぞれを単独に校正する分離校正の準備を進めている。分離校正の利点は，校正機関側では，ユーザー電離箱を，高分解能・全自動の標準電位計に接続して校正ができ，電離箱校正に限れば，精度を保ちつつも供給能力が上がることであり，ユーザ側からみれば，故障・修理の際，修理した電位計または電離箱のみを校正依頼できる．電離箱と電位計を自由に組み合わせられる（線量計の冗長性が確保できる）ことなである。現在，校正のための機器の整備および手順確定などがほぼ終了し，平成29年度の校正開始に向け，システムの構築および製品評価技術基盤機構への登録事業者申請および技能試験実施のための準備を進めている

An outline of separated calibration service currently under development

治療用線量計の2次校正機関である医用原子力財団では，校正サービスの次のステップとして，電位計と電離箱のそれぞれを単独に校正する分離校正の準備を進めている。分離校正の利点は，校正機関側としては，ユーザー電離箱を，高分解能・全自動の標準電位計に接続して校正ができ，また電離箱校正に限れば，精度を保ちつつも供給能力が上がる点にあり，ユーザー側としては，故障・修理の際，修理した電位計または電離箱のみを校正依頼できる．電離箱と電位計を自由に組み合わせられる（線量計の冗長性が確保できる）があげられる。現在，校正のための機器の整備および校正手法の確定がほぼ終わり，平成29年度の校正開始に向けて，システムの構築や機器の性能評価および製品評価技術基盤機構へのJCSS校正事業者登録及び技能試験のための準備を引き続き行っている。第111回日本医学物理学会学術大